eTheRNA secures EUR 24 million to develop its TriMix mRNA-based immunotherapy

Brussels (Belgium), 14 March 2016 — eTheRNA immunotherapies, a spin-off from the Brussels University ‘Vrije Universiteit Brussel’ (VUB), secured EUR 24 million in a Series A investment round with venture capital enabling the company to continue the development of its proprietary TriMix mRNA-based immunotherapies for melanoma, breast cancer and infectious diseases. eTheRNA was founded in January […]